Varian Receives FDA "Breakthrough Device Designation" for its Cardiac Radioablation (CRA) System for Treatment of Refractory Ventricular Tachycardia (VT)

Varian's CRA system has been designated a "breakthrough device" by the FDA because of its potential to offer a more effective treatment for select patients with refractory VT. Technology being developed will be assessed in clinical studies as ... Devices, Cardiology, FDA Varian, Cardiac Radioablation, Ventricular Tachycardia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news